First, it was difficult to collect a large sample of non-tumor brain tissue and low-grade human gliomas to validate GRPEL2 expression, although we performed a large-scale analysis of the TCGA and CGGA datasets to demonstrate that GRPEL2 is a biomarker related to WHO pathological grading and survival outcome. This evidence concerns the gene GRPEL2 and central nervous system cancer.